Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Daly

Showing results (351-360 of 397) with videos related to

Pageof 40
Sort By:
Pharmacogenetics|June 1, 1996
Nomenclature for human CYP2D6 allelesA K Daly, J Brockmöller, F Broly, et al.
Clinical Pharmacology and Therapeutics|July 1, 2020
PharmVar GeneFocus: CYP2C19Mariana R Botton, Michelle Whirl-Carrillo, Andria L Del Tredici, et al.
Journal of the National Cancer Institute|August 20, 1997
CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in TaiwanA Hildesheim, L M Anderson, C J Chen, et al.
Pharmacogenomics|December 23, 2010
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and PharmacogenomicsLaurent Becquemont, Ana Alfirevic, Ursula Amstutz, et al.
Clinical Pharmacology and Therapeutics|November 2, 2020
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug RegimensPaola Nicoletti, Harshad Devarbhavi, Ashish Goel, et al.
Pharmacogenomics|October 22, 2009
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designRianne M F van Schie, M I A Wadelius, Farhad Kamali, et al.
Nature Genetics|June 2, 2009
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinAnn K Daly, Peter T Donaldson, Pallav Bhatnagar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 14, 2002
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismBernard Lerer, Ronnen H Segman, Heiner Fangerau, et al.
Pharmacogenomics|September 13, 2012
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costsTalitha I Verhoef, William K Redekop, Rianne Mf van Schie, et al.
The New England Journal of Medicine|November 21, 2013
A randomized trial of genotype-guided dosing of warfarinMunir Pirmohamed, Girvan Burnside, Niclas Eriksson, et al.
Pageof 40

Showing results (351-360 of 397) with videos related to

Sort By:
Pageof 40
Pharmacogenetics|June 1, 1996
Nomenclature for human CYP2D6 allelesA K Daly, J Brockmöller, F Broly, et al.
Clinical Pharmacology and Therapeutics|July 1, 2020
PharmVar GeneFocus: CYP2C19Mariana R Botton, Michelle Whirl-Carrillo, Andria L Del Tredici, et al.
Journal of the National Cancer Institute|August 20, 1997
CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in TaiwanA Hildesheim, L M Anderson, C J Chen, et al.
Pharmacogenomics|December 23, 2010
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and PharmacogenomicsLaurent Becquemont, Ana Alfirevic, Ursula Amstutz, et al.
Clinical Pharmacology and Therapeutics|November 2, 2020
Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug RegimensPaola Nicoletti, Harshad Devarbhavi, Ashish Goel, et al.
Pharmacogenomics|October 22, 2009
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial designRianne M F van Schie, M I A Wadelius, Farhad Kamali, et al.
Nature Genetics|June 2, 2009
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinAnn K Daly, Peter T Donaldson, Pallav Bhatnagar, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 14, 2002
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphismBernard Lerer, Ronnen H Segman, Heiner Fangerau, et al.
Pharmacogenomics|September 13, 2012
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costsTalitha I Verhoef, William K Redekop, Rianne Mf van Schie, et al.
The New England Journal of Medicine|November 21, 2013
A randomized trial of genotype-guided dosing of warfarinMunir Pirmohamed, Girvan Burnside, Niclas Eriksson, et al.
Pageof 40